SCHEMBL2219660

SCHEMBL2219660

CC(OC(C)[Si](C)(C)C)[Si](C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3869822 0.79
SCHEMBL845124 0.72
SCHEMBL5521944 0.69
SCHEMBL5892717 0.69
SCHEMBL9891729 0.69
Hydrochloric Acid SCHEMBL866239 0.69
SCHEMBL1536343 0.69
SCHEMBL14552664 0.69
SCHEMBL4616294 0.69
SCHEMBL7603902 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637456-B2 Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate ADVERIO PHARMA GMBH (DE) 2026-05-26 US disclosed
CN-119954802-A Process for preparing compounds 阿德弗里奥药品有限责任公司 2025-05-09 CN disclosed
CN-119954803-A Process for preparing compounds 阿德弗里奥药品有限责任公司 2025-05-09 CN disclosed
CN-115697978-B Process for preparing methyl {4, 6-diamino-2- [ 5-fluoro-1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b ] pyridin-3-yl ] pyrimidin-5-yl } carbamate 阿德弗里奥药品有限责任公司 2025-02-28 CN disclosed
WO-2024254601-A1 HPGD INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. (US) 2024-12-12 WO disclosed
US-20230219952-A1 PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3 -YL]PYRIMIDIN-5-YL} CARBAMATE ADVERIO PHARMA GMBH (DE) 2023-07-13 US disclosed
EP-4165028-A1 PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE Adverio Pharma GmbH (DE) 2023-04-19 EP disclosed
CN-115697978-A Method for preparing methyl {4,6-diamino-2- [ 5-fluoro-1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b ] pyridin-3-yl ] pyrimidin-5-yl } carbamate 阿德弗里奥药品有限责任公司 2023-02-03 CN disclosed
WO-2021254981-A1 PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE ADVERIO PHARMA GMBH (DE) 2021-12-23 WO disclosed
EP-3925953-A1 PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}CARBAMATE Adverio Pharma GmbH (DE) 2021-12-22 EP disclosed
WO-2002020558-A2 METHOD FOR BINDING, IN SOLUTION, A PEPTIDE AND A LIPOPHILIC VECTOR AND USES THEREOF INSTITUT PASTEUR DE LILLE (FR) 2002-03-14 WO disclosed
WO-2001009173-A2 USE OF QUINIC, SHIKIMIC ACIDS AND THEIR DERIVATIVES FOR PREPARING MANNOSE RECEPTOR LIGANDS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNR S) (FR) 2001-02-08 WO disclosed
US-6140361-A FOR INHIBITING BINDING OF HUMAN IMMUNODEFICIENCY VIRUS REV PROTEIN TO REV RESPONSIVE ELEMENTS (RRE) SCRIPTGEN PHARMACEUTICALS, INC. (US) 2000-10-31 US disclosed
US-5942547-A FOR INHIBITING BINDING OF HUMAN IMMUNODEFICIENCY VIRUS PROTEIN TO RESPONSIVE ELEMENT; TREATMENT OF AIDS SCRIPTGEN PHARMACEUTICALS, INC. (US) 1999-08-24 US disclosed
EP-0865283-A1 2-DEOXYSTREPTAMINE AS A MOLECULAR SCAFFOLD FOR PREPARING FUNCTIONALLY AND SPACIALLY DIVERSE MOLECULES AND PHARMACEUTICAL COMPOSITIONS THEREOF Scriptgen Pharmaceuticals Inc. (US) 1998-09-23 EP disclosed
WO-1997009053-A9 2-DEOXYSTREPTAMINE AS A MOLECULAR SCAFFOLD FOR PREPARING FUNCTIONALLY AND SPATIALLY DIVERSE MOLECULES AND PHARMACEUTICAL COMPOSITIONS THEREOF 1997-05-01 WO disclosed
EP-0767791-A1 ARYL, ALKYL, ALKENYL AND ALKYNYLMACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY MERCK & CO. INC. (US) 1997-04-16 EP disclosed
WO-1997009053-A1 2-DEOXYSTREPTAMINE AS A MOLECULAR SCAFFOLD FOR PREPARING FUNCTIONALLY AND SPATIALLY DIVERSE MOLECULES AND PHARMACEUTICAL COMPOSITIONS THEREOF SCRIPTGEN PHARMACEUTICALS, INC. (US) 1997-03-13 WO disclosed
US-5550233-A AUTOIMMUNE DISEASES; PREVENTION OF TRANSPLANT REJECTION MERCK & CO., INC. (US) 1996-08-27 US disclosed
WO-1995035299-A1 ARYL, ALKYL, ALKENYL AND ALKYNYLMACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY MERCK & CO., INC. (US) 1995-12-28 WO disclosed